Werewolf Accounts Payable vs Current Deferred Revenue Analysis
| HOWL Stock | USD 1.78 0.14 8.54% |
Werewolf Therapeutics financial indicator trend analysis is more than just analyzing Werewolf Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Werewolf Therapeutics is a good investment. Please check the relationship between Werewolf Therapeutics Accounts Payable and its Current Deferred Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.
Accounts Payable vs Current Deferred Revenue
Accounts Payable vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Werewolf Therapeutics Accounts Payable account and Current Deferred Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Werewolf Therapeutics' Accounts Payable and Current Deferred Revenue is -0.45. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Werewolf Therapeutics, assuming nothing else is changed. The correlation between historical values of Werewolf Therapeutics' Accounts Payable and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Werewolf Therapeutics are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Accounts Payable i.e., Werewolf Therapeutics' Accounts Payable and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | -0.45 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Accounts Payable
An accounting item on the balance sheet that represents Werewolf Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Werewolf Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Werewolf Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Werewolf Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.Sales General And Administrative To Revenue is expected to rise to 1.14 this year, although the value of Selling General Administrative will most likely fall to about 13.5 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 216K | 1.1M | 3.1M | 3.3M | Depreciation And Amortization | 216K | 1.1M | 1.8M | 951.3K |
Werewolf Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Werewolf Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.082 | Quarterly Revenue Growth (0.86) | Return On Assets (0.26) | Return On Equity (0.62) |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.